eTable 2. Current key studies on the pharmacotherapy of urinary incontinence in women.

n	Comparison	Study design	Primary endpoint	Results [95% CI]	Adverse events
Study: Chapple et al. (2013) (e18)
928	mirabegron 25, 50, 100, 200 mg vs. placebo vs. tolterodin (ER) 4 mg	RCT single-/double-blinded, placebo-controlled	reduction of urinary frequency/24 hr	[- 1,9; – 2,1] ; [2,1; – 2,2] vs. 1.4 vs. 2.0*	increased heart rate with mirabegron 100 (1.3%) and 200 (3%) mg vs. placebo (0.6%) vs. tolterodine (1.2%)
Study: Wagg et al. (2017) (e19)
4040	fesoterodine 4 or 8 mg vs. placebo	RCT, double-blinded, placebo-controlled	reduction of urinary incontinence episodes and urinary frequency/24 hr	– 1.1 vs. – 0.5* – 2.4 vs. – 1.5*	dose reduction because of side effects: fesoterodine 4 mg 3%, 8 mg 1%, placebo 1%
Study: Nitti et al. (2013) (e20)
557	botulinum toxin 100 U vs. placebo at 12 weeks	RCT double-blinded, placebo-controlled, multicenter phase 3 trial	reduction of the number of incontinence episodes per day	– 2.65 vs. – 0.87* complete continence 22.9 % vs. 6.5%	uncomplicated urinary tract infection 15.5 % vs. 5.9 %intermittent self-catheterization 6.1 % vs. 0 %
Study: Sand et al. (2017) (e21)
261	desmopressin 25 μg vs. placebo	randomized, double-blinded, multicenter, placebo-controlled	reduction of nocturia	– 1.46 vs. 1.24*	none
Study: Mirzaei et al. (2021) (e22)
60	solifenacin (10 mg) vs. duloxetin (20 mg)	RCT, single-blinded	questionnaire (ICIQ-OAB)	from 14.86 to 9.66* vs. from 13.90 to 8.76* no difference between groups	side effects: dry mouth, lack of appetite 33.3% and 20% vs. 26.7% and 16.7%*

CI, confidence interval; ICIQ-OAB, International Consultation on Incontinence Questionnaire – Overactive bladder; RCT, randomized controlled trial; *p ≤ 0.05